To date, several substances have been developed to target the AR signaling axis, and some of them are used clinically for BPH and prostate cancer (Roehrborn et al., 1999; Roehrborn et al., 2002; Roehrborn et al., 2003; Saranyutanon et al., 2019). This evidence concerns the gene AR and Familial prostate cancer.